As of 2024-07-27, the EV/EBITDA ratio of Novavax Inc (NVAX) is -6.66. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Novavax's latest enterprise value is 2,151.33 mil USD. Novavax's TTM EBITDA according to its financial statements is -322.79 mil USD. Dividing these 2 quantities gives us the above Novavax EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.8x - 28.8x | 22.2x |
| Forward P/E multiples | 23.8x - 34.7x | 30.6x |
| Fair Price | (52.87) - (64.37) | (58.90) |
| Upside | -409.0% - -476.2% | -444.2% |
| Date | EV/EBITDA |
| 2024-07-26 | -6.66 |
| 2024-07-25 | -6.47 |
| 2024-07-24 | -5.92 |
| 2024-07-23 | -6.35 |
| 2024-07-22 | -5.72 |
| 2024-07-19 | -5.25 |
| 2024-07-18 | -5.73 |
| 2024-07-17 | -6.12 |
| 2024-07-16 | -6.37 |
| 2024-07-15 | -5.80 |
| 2024-07-12 | -4.92 |
| 2024-07-11 | -4.86 |
| 2024-07-10 | -4.42 |
| 2024-07-09 | -4.37 |
| 2024-07-08 | -4.47 |
| 2024-07-05 | -4.40 |
| 2024-07-03 | -4.68 |
| 2024-07-02 | -4.86 |
| 2024-07-01 | -4.76 |
| 2024-06-28 | -4.73 |
| 2024-06-27 | -4.80 |
| 2024-06-26 | -4.92 |
| 2024-06-25 | -5.31 |
| 2024-06-24 | -5.32 |
| 2024-06-21 | -5.31 |
| 2024-06-20 | -5.34 |
| 2024-06-18 | -5.22 |
| 2024-06-17 | -5.33 |
| 2024-06-14 | -5.49 |
| 2024-06-13 | -5.77 |
| 2024-06-12 | -6.12 |
| 2024-06-11 | -6.50 |
| 2024-06-10 | -6.18 |
| 2024-06-07 | -7.13 |
| 2024-06-06 | -7.73 |
| 2024-06-05 | -8.34 |
| 2024-06-04 | -6.95 |
| 2024-06-03 | -7.15 |
| 2024-05-31 | -5.76 |
| 2024-05-30 | -5.86 |
| 2024-05-29 | -5.79 |
| 2024-05-28 | -5.97 |
| 2024-05-24 | -5.96 |
| 2024-05-23 | -5.81 |
| 2024-05-22 | -6.05 |
| 2024-05-21 | -5.71 |
| 2024-05-20 | -5.66 |
| 2024-05-17 | -4.88 |
| 2024-05-16 | -5.49 |
| 2024-05-15 | -4.83 |